The risk of transfusion-transmitted viral infections

New England Journal of Medicine

Volumn 334, Issue 26, 1996, Pages 1685-1690

  Schreiber, George B ^a   Busch, Michael P ^b   Kleinman, Steven H ^c   Korelitz, James J ^a  

^a WESTAT   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD DONOR; BLOOD TRANSFUSION REACTION; CLINICAL PROTOCOL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS; HUMAN T CELL LEUKEMIA VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING TEST; SEROCONVERSION; VIRUS INFECTION; VIRUS TRANSMISSION;

ANTIBODIES, VIRAL; BLOOD; BLOOD DONORS; BLOOD TRANSFUSION; DELTARETROVIRUS INFECTIONS; DISEASE TRANSMISSION, HORIZONTAL; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; RISK; SEROLOGIC TESTS; VIRUS DISEASES;

EID: 0029942003     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199606273342601     Document Type: Article

References (41)

1. Dodd RY. Adverse consequences of blood transfusion: quantitative risk estimates. In: Nance ST, ed. Blood supply: risk, perceptions and prospects for the future. Bethesda, Md.: American Association of Blood Banks, 1994:1-24.
2. Kleinman S. Donor selection and screening procedures. In: Nance ST, ed. Blood safety: current challenges. Bethesda, Md.: American Association of Blood Banks, 1992:169-200.
3. Alter HJ. To C or not to C: these are the questions. Blood 1995;85:1681-5.
4. Aach RD, Szmuness W, Mosley JW, et al. Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients: the Transfusion-Transmitted Viruses Study. N Engl J Med 1981;304:989-94.
5. Donegan E, Stuart M, Niland JC, et al. Infection with human immunodeficiency virus type 1 (HIV-I) among recipients of antibody-positive blood donations. Ann Intern Med 1990;113:733-9.
6. Nelson KE, Donahue JG, Munoz A, et al. Transmission of retroviruses from seronegative donors by transfusion during cardiac surgery: a multicenter study of HIV-I and HTLV-I/II infections. Ann Intern Med 1992;117:554-9.
7. Alter HJ, Purcell RH, Holland PV, Alling DW, Koziol DE. Donor transaminase and recipient hepatitis: impact on blood transfusion services. JAMA 1981;246:630-4.
8. Alter HJ, Epstein JS, Swenson SG, et al. Prevalence of human immunodeficiency virus type 1 p24 antigen in U.S. blood donors - an assessment of the efficacy of testing in donor screening. N Engl J Med 1990;323:1312-7.
9. Busch MP, Eble BE, Khayam-Bashi H, et al. Evaluation of screened blood donations for human immunodeficiency virus type 1 infection by culture and DNA amplification of pooled cells. N Engl J Med 1991;325:1-5.
10. Kleinman S, Alter H, Busch M, et al. Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-antigen HCV enzyme immunoassay. Transfusion 1992;32:805-13.
11. Aach RD, Stevens CE, Hollinger FB, et al. Hepatitis C virus infection in post-transfusion hepatitis - an analysis with first- and second-generation assays. N Engl J Med 1991;325:1325-9.
12. Zuck TF, Thomson RA, Schreiber GB, et al. The Retrovirus Epidemiology Donor Study (REDS): rationale and methods. Transfusion 1995;35:944-51.
13. Busch MP, Laycock M, Kleinman SH, et al. Accuracy of supplementary serologic testing for human T-lymphotropic virus types I and II in US blood donors. Blood 1994;83:1143-8.
14. Korelitz JJ, Williams AE, Busch MP, et al. Demographic characteristics and prevalence of serologic markers among donors who use the confidential unit exclusion process: the Retrovirus Epidemiology Donor Study. Transfusion 1994;34:870-6.
15. Sayre KR, Dodd RY, Tegtmeier G, Layug L, Alexander SS, Busch MP. False-positive human immunodeficiency virus type 1 Western blot tests in noninfected blood donors. Transfusion 1996;36:45-52.
16. Strauss D, Valinsky JE, Kessler D, Bianco C. Decreased specificity of HBsAg confirmation as a result of decreased specificity of screening test. Transfusion 1994;34:34S. abstract.
17. Kleinman SH, Kaplan JE, Khabbaz RF, Calabro MA, Thomson R, Busch M. Evaluation of a p21e-spiked Western blot (immunoblot) in confirming human T-cell lymphotropic virus type I or II infection in volunteer blood donors. J Clin Microbiol 1994;32:603-7.
18. Busch MP, Tobler L, Quan S, et al. A pattern of 5-1-1 and C100-3 only on hepatitis C virus (HCV) recombinant immunoblot assay does not reflect HCV infection in blood donors. Transfusion 1993;33:84-8.
19. Hoofnagle JH, Seeff LB, Buskell Bales Z, Gerety RJ, Tabor E Serologic responses in HB, In: Vyas GN, Cohen SN, Schmid R, eds. Viral hepatitis: a contemporary assessment of etiology, epidemiology, pathogenesis and prevention. Philadelphia: Franklin Institute Press, 1978:219-42.
20. Mimms LT, Mosley JW, Hollinger FB, et al. Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. BMJ 1993;307:1095-7.
21. Hughes W, Barr A, Dow BC, Follett EAC, Barbara JAJ. A multicentre assessment of the specificity of ten anti-HBc screening tests. Transfus Med 1995;5:225-30.
22. Busch MP, Lee LL, Satten GA, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion 1995;35:91-7.
23. Manns A, Wilks RJ, Murphy EL, et al. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer 1992;51:886-91.
24. Busch MP, Korelitz JJ, Kleinman SH, et al. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. Transfusion 1995;35:903-10.
25. Lelie PN, Cuypers HT, Reesink HW, et al. Patterns of serological markers in transfusion-transmitted hepatitis C virus infection using second-generation HCV assays. J Med Virol:1992;37:203-9.
26. Jagodzinski L, Kraus F, Garrett P, Schumacher R, Manak M. Detection of hepatitis B viral sequences in early HBV infection. Transfusion 1994;34: Suppl:37S. abstract.
27. Renzullo PO, McNeil JG, Wann ZF, Burke DS, Brundage JF, United States Military Medical Consortium for Applied Retroviral Research. Human immunodeficiency virus type-1 seroconversion trends among young adults serving in the United States Army, 1985-1993. J Acquir Immune Defic Syndr 1995;10:177-85.
28. Alter MJ, Margolis HS, Krawczynski K, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327: 1899-905.
29. Summaries of notifiable diseases, United States, 1993. MMWR Morb Mortal Wkly Rep 1994;42(53):1-12.
30. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR Morb Mortal Wkly Rep 1991;40(RR-4):1-17.
31. Alter HJ, Purcell RH, Shin JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-500.
32. Donegan E, Lee TH, Operskalski EA, et al. Transfusion transmission of retroviruses: human T-lymphotropic virus types I and II compared with human immunodeficiency virus type I. Transfusion 1994;34:478-83.
33. Kleinman S, Busch MP. General overview of transfusion-transmitted infections. In: Petz LD, Swisher SN, Kleinman S, Spence RK, Strauss RG, eds. Clinical practice of transfusion medicine. 3rd ed. New York: Churchill Livingstone, 1996:809-21.
34. Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995;333:1721-5.
35. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992;327:1906-11.
36. Farci P, Alter HJ, Wong D, et al. A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. N Engl J Med 1991;325:98-104.
37. Iwarson S, Norkrans G, Wejstal R. Hepatitis C: natural history of a unique infection. Clin Infect Dis 1995;20:1361-70.
38. Cumming PD, Wallace EL, Schorr JB, Dodd RY. Exposure of patients to human immunodeficiency virus through the transfusion of blood components that test antibody-negative. N Engl J Med 1989;321:941-6.
39. Petersen LR, Satten GA, Dodd R, et al. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. Transfusion 1994;34:283-9.
40. Hjelle B, Wilson C, Cyrus S, et al. Human T-cell leukemia virus type II infection frequently goes undetected in contemporary US blood donors Blood 1993;81:1641-4.
41. AuBuchon JP, Birkmeyer JD, Busch MP. Cost-effectiveness of expanded HIV test protocols for donated blood. Transfusion 1995;35:Suppl-43S abstract.